tiprankstipranks
AdAlta Ltd. (AU:1AD)
ASX:1AD
Australian Market
Holding AU:1AD?
Track your performance easily

AdAlta Ltd. (1AD) Share Price & Analysis

4 Followers

1AD Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.27%99.73%
― Other Institutional Investors
99.73% Public Companies and
Individual Investors

1AD FAQ

What was AdAlta Ltd.’s price range in the past 12 months?
AdAlta Ltd. lowest share price was AU$0.02 and its highest was AU$0.04 in the past 12 months.
    What is AdAlta Ltd.’s market cap?
    Currently, no data Available
    When is AdAlta Ltd.’s upcoming earnings report date?
    AdAlta Ltd.’s upcoming earnings report date is Mar 03, 2025 which is in 101 days.
      How were AdAlta Ltd.’s earnings last quarter?
      AdAlta Ltd. released its earnings results on Aug 28, 2024. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
        Is AdAlta Ltd. overvalued?
        According to Wall Street analysts AdAlta Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does AdAlta Ltd. pay dividends?
          AdAlta Ltd. does not currently pay dividends.
          What is AdAlta Ltd.’s EPS estimate?
          AdAlta Ltd.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does AdAlta Ltd. have?
          AdAlta Ltd. has 631,458,070 shares outstanding.
            What happened to AdAlta Ltd.’s price movement after its last earnings report?
            AdAlta Ltd. reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of AdAlta Ltd.?
              Currently, no hedge funds are holding shares in AU:1AD
              ---

              Company Description

              AdAlta Ltd.

              AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              PYC Therapeutics Limited
              Race Oncology Ltd.
              Tissue Repair Ltd
              BCAL Diagnostics Limited
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis